LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received lurbinectedin as part of the French Early Access Program (ATU). Previous and subsequent treatments (treatment delivered immediately after treatment with lurbinectedin) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.
Study Type
OBSERVATIONAL
Enrollment
312
Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
Institut Curie
Paris, France
Villefranche-Sur-Saône - CH
Villefranche-sur-Saône, France
demographic and clinical characteristics of patients
age
Time frame: 8 months
demographic and clinical characteristics of patients
sex
Time frame: 8 months
demographic and clinical characteristics of patients
clinical stage
Time frame: 8 months
demographic and clinical characteristics of patients
prior therapy
Time frame: 8 months
Overall Survival (OS)
OS is defined as the time from the first dose of treatment with lurbinectedin to death from any cause
Time frame: 8 months
Real-world progression-free survival
time from first dose of treatment with lurbinectedin to first occurrence of disease progression or death from any cause during the study
Time frame: 8 months
Best response
best response recorded from the start of treatment with lurbinectedin until disease progression or start of further anti-cancer treatment
Time frame: 8 months
Duration of treatment
time from first dose of treatment to discontinuation of treatment (interruption of more than 2 months) with lurbinectedin
Time frame: 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pattern of tumor progression
site of disease progression after treatment with lurbinectedin
Time frame: 8 months
Duration of treatment with lurbinectedin beyond progression
time between first occurrence of disease progression and treatment discontinuation
Time frame: 8 months
Adverse Drug Reaction
maximal grade 3-4-5 treatment-related adverse events (SAEs, TRAEs), and immune-related events will be recorded for each patient
Time frame: 8 months